Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Lowered to $425.00 at Chardan Capital

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price objective trimmed by Chardan Capital from $475.00 to $425.00 in a report issued on Friday,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other equities research analysts have also recently issued reports on ALNY. Leerink Partners reduced their target price on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating for the company in a research report on Monday, December 15th. Morgan Stanley dropped their price objective on shares of Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating for the company in a research note on Friday, January 30th. HC Wainwright decreased their target price on shares of Alnylam Pharmaceuticals from $570.00 to $510.00 and set a “buy” rating on the stock in a research report on Friday, January 30th. Raymond James Financial reaffirmed an “outperform” rating and set a $472.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, January 12th. Finally, Oppenheimer began coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, January 7th. They issued an “outperform” rating and a $500.00 price target for the company. Twenty-two research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $477.38.

Alnylam Pharmaceuticals Trading Up 1.9%

Shares of NASDAQ:ALNY opened at $314.40 on Friday. Alnylam Pharmaceuticals has a 12-month low of $205.87 and a 12-month high of $495.55. The business has a 50 day moving average of $374.98 and a 200-day moving average of $424.03. The company has a quick ratio of 2.49, a current ratio of 2.54 and a debt-to-equity ratio of 4.45. The stock has a market cap of $41.54 billion, a PE ratio of 183.86 and a beta of 0.35.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, February 12th. The biopharmaceutical company reported $0.82 earnings per share for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.61). The firm had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.16 billion. Alnylam Pharmaceuticals had a return on equity of 119.85% and a net margin of 6.43%.Alnylam Pharmaceuticals’s revenue for the quarter was up 84.9% on a year-over-year basis. During the same quarter last year, the business posted ($0.65) EPS. As a group, equities research analysts forecast that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,510 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $362.87, for a total value of $547,933.70. Following the transaction, the executive vice president owned 29,728 shares in the company, valued at $10,787,399.36. The trade was a 4.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Kevin Joseph Fitzgerald sold 12,128 shares of the stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $452.18, for a total transaction of $5,484,039.04. Following the completion of the transaction, the executive vice president directly owned 21,264 shares of the company’s stock, valued at $9,615,155.52. This trade represents a 36.32% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 31,305 shares of company stock worth $12,459,785. 1.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in ALNY. Root Financial Partners LLC acquired a new stake in Alnylam Pharmaceuticals in the third quarter valued at approximately $25,000. Salomon & Ludwin LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at $27,000. HM Payson & Co. bought a new stake in Alnylam Pharmaceuticals during the 4th quarter worth $27,000. Golden State Wealth Management LLC increased its holdings in Alnylam Pharmaceuticals by 100.0% in the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 36 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd bought a new position in Alnylam Pharmaceuticals in the third quarter valued at about $29,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Amvuttra is powering large revenue gains and Alnylam reported full-year product revenues near $3B with strong year‑over‑year growth; the company also reported profitability for the first time — a clear fundamental positive for long‑term earnings potential. Business Wire: Alnylam Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Catalyst from analyst support — some firms (e.g., TD Cowen) are maintaining Buy ratings and framing Amvuttra as the catalyst for a longer‑term profitability inflection. TipRanks: Amvuttra-Driven Profitability Inflection Supports Buy Rating
• Neutral Sentiment: FY‑2026 revenue guidance was updated to roughly $5.3–$5.8B (slightly wide band vs. consensus), leaving mixed readthroughs for near‑term estimates and valuation models. Business Wire: FY‑2026 Guidance
• Neutral Sentiment: Analysts have trimmed price targets (e.g., Chardan, Needham) but many kept Buy ratings — this tempers upside expectations while still signaling continued institutional conviction. Benzinga: Analyst Price Target Changes
• Negative Sentiment: Market reaction to the Q4 release was mixed: some outlets flagged EPS and revenue misses vs. specific consensus numbers while others reported an EPS beat — the inconsistent takeaways have created volatility and investor uncertainty. Zacks: Q4 Earnings Beat, Sales Miss MarketBeat: Q4 Snapshot
• Negative Sentiment: Management signaled higher long‑term R&D/spend to fund pipeline ambitions and flagged execution/scaling risks for global Amvuttra rollout — comments that prompted some investors to downgrade longer‑term profit expectations. Seeking Alpha: Investors Revise Future Profit Expectations TipRanks: Execution Risks Loom
• Neutral Sentiment: Reported short‑interest figures in the feeds are effectively zero/placeholder and not informative for current positioning — ignore as a market signal until clearer data is posted.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.